Insilico Medicine vs Exa
A side-by-side look at scores, pricing and features — with RECATOOLS' ASEAN-aware verdict for each.
|
|
Exa
Web search and retrieval API built for AI agents and apps
Visit
|
|
|---|---|---|
| RECATOOLS Score | 8.7 / 10 | 7.7 / 10 |
| Capability | ||
| Value for money | ||
| Ease of use | ||
| ASEAN readiness | ||
| API quality | ||
| Pricing | Enterprise | Freemium |
| Free tier | Chemistry42 cloud offers academic/startup access tiers; contact required | 20,000 search requests per month on the free plan; startup and education grants of $1,000 in free API credits also available |
| Paid from | Enterprise licensing; upfront deals from $10M milestone to $115M (Lilly) | API search billed at $7 per 1,000 requests (as of March 2026 pricing update) |
| Has API | ✓ | ✓ |
| Open source | ✗ | ✗ |
| Free to use | ✗ | ✓ |
| Users | 13 of top 20 global pharma cos; 18.3% YoY subscription growth (2025) | — |
| Founded | 2014 | 2021 |
| Maker | Insilico Medicine (independent; HKEX: 3696) | — |
| Verdict | Insilico Medicine holds a lead no other AI-native drug company currently matches: a molecule it designed from scratch has reached Phase III, with published peer-reviewed efficacy data behind it. The Pharma.AI stack — Pan... |
Exa earns its credibility through customer names, not just claims: Cursor, Notion AI, Cognition and OpenRouter all use it in production, and a $250M Series C at a $2.2B valuation (May 2026, led by a16z) backs that up. Th... |
| Full review → | Full review → |
← Back to AI Directory
Comparisons cover up to 4 tools. Scores are RECATOOLS editorial assessments; verify current pricing on each vendor's site.